Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
Sponsor: Shanghai JMT-Bio Inc.
Summary
Use these resources to provide understandable information about this study to patients, families, and health care providers:
Official title: Identify the Expanded Access Program, if Any. This is Required Unless the Expanded Access Type is "Individual Patients." A Randomized, Parallel, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JMT206 Injection Alone or in Combination With Semaglutide in Obese Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-10-20
Completion Date
2027-04-30
Last Updated
2026-09-25
Healthy Volunteers
No
Conditions
Interventions
JMT206 injection
JMT206 injection administered subcutaneously (SC) once a week
Semaglutide injection
Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.
Placebo injection
Placebo administered subcutaneously (SC) once a week.
Locations (1)
Peking University People's Hospital
Beijing, China